Compare STTK & OLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | OLP |
|---|---|---|
| Founded | 2016 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.3M | 551.6M |
| IPO Year | 2020 | 1995 |
| Metric | STTK | OLP |
|---|---|---|
| Price | $7.36 | $25.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $10.00 | ★ $26.75 |
| AVG Volume (30 Days) | ★ 1.9M | 82.0K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 7.88% |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ 0.28 |
| Revenue | $1,000,000.00 | ★ $82,740,000.00 |
| Revenue This Year | N/A | $11.98 |
| Revenue Next Year | N/A | $3.71 |
| P/E Ratio | ★ N/A | $88.82 |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $0.71 | $19.62 |
| 52 Week High | $8.33 | $25.88 |
| Indicator | STTK | OLP |
|---|---|---|
| Relative Strength Index (RSI) | 58.96 | 55.33 |
| Support Level | $5.87 | $24.40 |
| Resistance Level | $7.64 | $25.49 |
| Average True Range (ATR) | 0.62 | 0.61 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 71.63 | 46.62 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.